Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.01
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is underpriced on P/FCF.
Data is available to registered users only
Buy
Sell